1. No category

Prostate Studies
1. Health Canada (2008). Natural Health Product Monograph: Stinging Nettle. Natural Health Product Ingredients
Database. Retrieved from: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=166&lang=eng
2. Health Canada (2009). Natural Health Product Monograph: Lycopene. Natural Health Product Ingredients
Database. Retrieved from:http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=166&lang=eng
3. Health Canada (2009). Natural Health Product Monograph: Zinc (from non-picolinate sources). Natural Health
Product Ingredients Database. Retrieved from:http://webprod.hc-sc.gc.ca/nhpidbdipsn/monoReq.do?id=192&lang=eng
4. Health Canada (2008). Natural Health Product Monograph: Rosemary - oral. Natural Health Product Ingredients
Database. Retrieved from:http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=155&lang=eng
5. Health Canada (2007). Natural Health Product Monograph: Selenium. Natural Health Product Ingredients
Database. Retrieved from:http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=161&lang=eng
6. Health Canada (2007). Natural Health Product Monograph: Vitamin D. Natural Health Product Ingredients
Database. Retrieved from:http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=183&lang=eng
7. Badmaev V, Majeed M, Prakash L (2000). Piperine derived from black pepper increases the plasma levels of
coenzyme Q10 following oral supplementation. Journal of Nutritional Biochemistry, 11:109-13.
8. Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, et al. (1991). Effects of piperine on bioavailability and
pharmacokinetics of propranolol and theophylline in healthy volunteers. European Journal of Clinical
Pharmacology, 41:615-7.
You can find us at: PNO.CA
9. Concon JM, Newburg DS, Swerczek TW. (1979). Black pepper (Piper nigrum): Evidence of carcinogenicity.
Nutrition and Cancer. 1:22-6.
10. Weinberg AM, Ingmanson DE, Shapiro AM, Hunter JE, Epstein SS. (1984). Cancer and diet. Science. 224:660-6.
11. Govindarajan VS (1977). Pepper – Chemistry, technology and quality evaluation. CRC Critical Reviews in Food
Science and Nutrition, 9:115-225.
12. Kasibhatta R, Naidu MUR. (2007). Influence of piperine on the pharmacokinetics of nevirapine under fasting
conditions. Drugs in Research and Development, 8:383-91.
13. Naidu KA, Thippeswamy NB. (2002). Inhibition of human low density lipoprotein oxidation by active principles
from spices. Molecular and Cellular Biochemistry, 229:19-23.
14. Acuff RV, Cai DJ, Dong ZP, Bell D. (2007). The lipid lowering effect of plant sterol ester capsules in
hypercholesterolemic subjects. Lipids in Health and Disease, 6:11.
15. Earnest CP, Mikus CR, Lemieux I, Arsenault BJ, Church TS. (2007). Examination of encapsulated phytosterols
ester supplementation on lipid indices associated with cardiovascular disease. Nutrition, 23:625-33.
16. Goldberg AC, Ostlund RE, Bateman JH, Schimmoeller L, McPherson TB, et al. (2006). Effect of plant stanols
tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. American Journal of
Cardiology, 97:376-9.
17. Jenkins DJA, Kendall CWC, Marchie A, Faulkner DA, Wong JMW, et al. (2003). Effects of a dietary portfolio of
choelster-lowering foods vs Lovastatin on serum lipids and C-reactive protein. Journal of the American Medical
Association, 290:503-10.
18. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, et al. (2003). Efficacy and safety of plant stanols and sterols
in the management of blood cholesterol levels. Mayo Clinical Proceedings, 78:965-78.
19. Law M (2000). Plant sterol and stanol margarines and health. British Medical JournaL, 20:861-4.
20. McPherson TB, Ostlund RD, Goldberg AC, Bateman JH, Schimmoeller, et al.. Phytostanol tablets reduce human
LDL-cholesterol. Journal of Pharmacy and Pharmacology, 57:889-96.
21. Ostlund RE. (2002). Phytosterols in human nutrition. Annual Review in Nutrition, 22:533-49.
22. Weidner C, Krempf M, Bard JM, Cazaubiel M, Bell D. (2008). Cholesterol lowering effect of a soy drink enriched
with plant sterols in a French population with moderate hypercholesterolemia. Lipids in Health Disease. 7:35.
23. Wolfs M, de Jong N, Ocke MC, Verhagen H, Verschuren WMM. (2006). Effectiveness of customary use of
phytosterols/-stanol enriched argarines in blood cholesterol lowering. Food and Chemical Toxicology, 44:1682-8.
24. Bell MC, Crowley-Norwick P, Bradlo HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, et al. (2000). Placecontrolled trial of indole-3-carbinol in the treatment of CIN. Gynecologic Oncology, 78:123-9.
You can find us at: PNO.CA
25. Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GY, et al. (1994). Long-term responses of women to
indole-3-carbinol or a high fiber diet. Cancer Epidemiology, Biomarkers and Prevention, 3:591-5.
26. McAlindon TE, Gulin J, Chen T, Klug T, Lahita R, et al. (2001). Indole-3-carbinol in women with SLE: effect on
estrogen metabolism and disease activity. Lupus. 10:779-83.
27. Michnovicz JJ. (1998). Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol.
International Journal of Obesity, 22:227-9.
28. Michnovicz JJ, Adlercreutz H, Bradlow HL. (1997). Changes in levels of urinary estrogen metabolites after oral
indole-3-carbinol treatment in humans. Journal of the National Cancer Institute, 89:718-23.
29. Michnovicz JJ, Bradlow HL. (1990). Induction of estradiol metabolism by dietary indole-3-carbinol in humans.
Journal of the National Cancer Institute, 82:947-9.
30. Minich DM, Bland JS. (2007). A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals.
Nutrition Reviews. 65:259-67.
31. Thorne Reearch Inc. (2005). Indole-3-Carbinol. Alternative Medicine Review. 10:337-42.
32. Naik R, Nixon S, Lopes A, Godfrey K, Hatem MH, et al. (2006). A randomized phase II trial of indole-3-carbinol in
the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer, 16:786-90.
33. Rosen CA, Bryson PC (2004). Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results.
Journal of Voice,18:248-53.
34. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL (1998). Preliminary results of the use of
indole-3-carbinol for recurrent respiratory papillomatosis. Otaryngology Head and Neck Surgery, 118:810-5.
35. Wong GYC, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP (1997). Dose-ranging study of indole-3carbinol for breast cancer prevention. Journal of Cellular Biochemistry Supplement, 28/29:111-6.
36. Dutkiewicz S. (1995). Usefulness of Cernilton in the treatment of Benign Prostatic Hyperplasia. International
Urology and Nephrology. 28:49-53.
37. Edwards JL. (2008). Diagnosis and management of benign prostatic hyperplasia. American Family Physician,
77:1403-10.
38. Elist J. (2006). Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients
with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebocontrolled study. Urology, 67:60-3.
39. MacDonald R, Ishani A, Rutks I, Wilt TJ. (1999). A systematic review of Cernilton for the treatment of benign
prostatic hyperplasia. British Journal of Urology International, 85:836-41.
40. Murphy AB, Macejko A, Taylor A, Nadler RB. (2009). Chronic prostatitis management strategies. Drugs, 69:71-84.
You can find us at: PNO.CA
41. Potts JM. (2005). Therapetic options for chronic prostatitis/chronic pelvic pain syndrome. Current Urology
Reports, 6:313-7.
42. Strong KM. (2004). African Plum and Benign Prostatic Hypertrophy. Journal of Herbal Pharmacotherapy, 4:41-6.
43. Wagenlehmer FME, Schneider H, Ludwig M, Schnitker J, Brahler E, Weidner W. (2009). A pollen extract
(Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre,
randomized, prospective, double-blind, placebo-controlled phase 3 study. European Urology, 56:544-51.
44. Wilt T, MacDonald R, Ishani A, Rutks I, Stark G. (1998). Cernilton for benign prostatic hyperplasia (Review). The
Cochrane collaboration. John Wiley & Sons, Ltd. Issue 4.
45. Thorne Research Inc. (2002). Monograph: Pygeum africanum (African plum tree). Alternative Medicine Review,
7:71-4.
46. Dedhia RC, McVary KT. (2008). Phytotherapy for lower urinary tract symptoms secondary to benign prostatic
hyperplasia. Journal of Urology, 179:2119-25.
47. Chatelain C, Autet W, Brackman F. (1999). Comparison of once and twice daily dosage forms of Pygeum
africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with longterm open label extension. Urology.,54:473-8.
48. Edgar AD, Levin R, Constantinou CE, Denis L. (2007). A critical review of the pharmacology of the plant extract of
Pygeum africanum in the treatment of LUTS. Neurourology and Urodynamics, 26:458-63.
49. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV. (2007). The efficacy of drugs for the treatment of
LUTS/BPH, a study in 6 European countries. European Urology, 51:207-16.
50. Ishani A, MacDonald R, Nelson D, Rutks I (2000). Pygeum africanum for the treatment of patients with benign
prostatic hyperplasia: a systematic review and quantitative meta-analysis. American Journal of Medicine,
109:654-64.
51. Natural health products directorate (NHPD, 2009). Website accessed on October 22, 2009 at http://www.hcsc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/lnhpd-bdpsnh-eng.php
52. Strong KM (2004). African Plum and Benign Prostatic Hypertrophy. Journal of Herbal Pharmacotherapy. 4:41-6.
53. Wilt T, Ishani A. (2009). Pygeum africanum for benign prostatic hyperplasia (Review). The Cochrane
collaboration. John Wiley & Sons, Ltd. Issue 4.
You can find us at: PNO.CA